Journal of Psychoactive Drugs · 2012 · 29 citations · 32 references
MedicinePharmacologyPharmacotherapyNeuropharmacologyPsychopharmacologySubstance Use DisordersAddictionAddiction AssessmentAddiction NeurobiologyBehavior TherapyDopaminergic PharmacologyDrug DependenceAgonist ActivityDopaminergic PathwaysEarly Intervention RegimesOral VariantsPost-treatment ComparisonReward MechanismsStriatal NeuroadaptationsSubstance Use Disorder Pharmacotherapy
Substance use disorders (SUD) are inheritable and the culprit is hypodopaminergic function regulated by reward genes. We evaluated a natural dopaminergic agonist; KB220 intravenous (IV) and oral variants, to improve dopaminergic function in SUD. Our pilot experiment found a significant reduction of chronic symptoms, measured by the Chronic Abstinence Symptom Severity (CASS) Scale. The combined group (IV and oral) did significantly better than the oral-only group over the first week and 30-day follow-up period. Next, the combination was given to 129 subjects and three factors; Emotion, Somatic, and Impaired Cognition, with eigenvalues greater than one were extracted for baseline CASS-Revised (CASS-R) variables. Paired sample t-tests for pre and post-treatment scales showed significant declines (p = .00001) from pre- to post-treatment: t = 19.1 for Emotion, t = 16.1 for Somatic, and t = 14.9 for Impaired Cognition. In a two-year follow-up of 23 subjects who underwent KB220IV therapy (at least five IV treatments over seven days) plus orals for 30+ days: 21 (91%) were sober at six months, 19 (82%) having no relapse; 19 (82%) were sober at one year, 18 (78%) having no relapse; and 21 (91%) were sober two-years post-treatment, 16(70%) having no relapse. We await additional research and advise caution in interpreting these encouraging results.
32
Overexpression of dopamine D2 receptors reduces alcohol self‐administration
Panayotis K. Thanos, Nora D. Volkow, Paul Freimuth et al. · Journal of Neurochemistry · 2001 · 325 citations
Medicine, Neurobiology, Neuroscience +17
Kenneth Blum, Eliot L. Gardner, Marlene Oscar‐Berman et al. · Current Pharmaceutical Design · 2012 · 214 citations